BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 2019;39 Suppl 1:19-31. [PMID: 30851228 DOI: 10.1111/liv.14095] [Cited by in Crossref: 104] [Cited by in F6Publishing: 195] [Article Influence: 34.7] [Reference Citation Analysis]
Number Citing Articles
1 Mattos VC, Nascimento FSD, Suzuki MO, Taba JV, Pipek LZ, Moraes WAF, Cortez VS, Kubrusly MS, Torsani MB, Iuamoto L, Hsing WT, Carneiro-D'Albuquerque LA, Meyer A, Andraus W. MICRObiota on BILIOpancreatic malignant diseases [MICROBILIO]: A systematic review. Clinics (Sao Paulo) 2022;77:100101. [PMID: 36122499 DOI: 10.1016/j.clinsp.2022.100101] [Reference Citation Analysis]
2 Abou-alfa GK, Bibeau K, Schultz N, Yaqubie A, Millang B, Ren H, Féliz L. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma. Targ Oncol. [DOI: 10.1007/s11523-022-00906-w] [Reference Citation Analysis]
3 Shaikh CF, Alaimo L, Moazzam Z, Endo Y, Lima HA, Dawood Z, Munir MM, Pawlik TM. Predicting overall and recurrence‐free survival in patients with intrahepatic cholangiocarcinoma using the MEGNA score: A multi‐institutional analysis. Journal of Surgical Oncology. [DOI: 10.1002/jso.27098] [Reference Citation Analysis]
4 Morgan MA, Khot R, Sundaram KM, Ludwig DR, Nair RT, Mittal PK, Ganeshan DM, Venkatesh SK. Primary sclerosing cholangitis: review for radiologists. Abdom Radiol (NY) 2022. [PMID: 36063181 DOI: 10.1007/s00261-022-03655-6] [Reference Citation Analysis]
5 Prinz C, Frese R, Grams M, Fehring L. Emerging Role of microRNA Dysregulation in Diagnosis and Prognosis of Extrahepatic Cholangiocarcinoma. Genes (Basel) 2022;13:1479. [PMID: 36011390 DOI: 10.3390/genes13081479] [Reference Citation Analysis]
6 Ebel S, Struck MF, van Boemmel F, Beeskow AB, Gößmann H, Denecke T. Chemosaturation of the Liver - an Update. Rofo 2022. [PMID: 35977553 DOI: 10.1055/a-1858-3418] [Reference Citation Analysis]
7 Vithayathil M, Khan SA. Current epidemiology of cholangiocarcinoma in western countries. J Hepatol 2022:S0168-8278(22)02988-9. [PMID: 35977611 DOI: 10.1016/j.jhep.2022.07.022] [Reference Citation Analysis]
8 Madoff DC, Abi-Jaoudeh N, Braxton D, Goyal L, Jain D, Odisio BC, Salem R, Schattner M, Sheth R, Li D. An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma. Oncologist 2022:oyac139. [PMID: 35925597 DOI: 10.1093/oncolo/oyac139] [Reference Citation Analysis]
9 Param NJ, Bramel ER, Sia D. The Molecular Pathogenesis and Targeted Therapies for Cholangiocarcinoma. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2022.05.006] [Reference Citation Analysis]
10 Zhang L, Ma D, Li F, Qiu G, Sun D, Zeng Z. Lnc-PKD2-2-3/miR-328/GPAM ceRNA Network Induces Cholangiocarcinoma Proliferation, Invasion and 5-FU Chemoresistance. Front Oncol 2022;12:871281. [DOI: 10.3389/fonc.2022.871281] [Reference Citation Analysis]
11 Lin CR, Lee YK, Chiang CJ, Yang YW, Chang HC, You SL. Secular trends of intrahepatic cholangiocarcinoma in a high endemic area: A population-based study. World J Gastroenterol 2022; 28(28): 3695-3705 [DOI: 10.3748/wjg.v28.i28.3695] [Reference Citation Analysis]
12 Haag F, Manikkam A, Kraft D, Bär C, Wilke V, Nowak AJ, Bertrand J, Omari J, Pech M, Gylstorff S, Relja B. Selective Internal Radiotherapy Changes the Immune Profiles of Extracellular Vesicles and Their Immune Origin in Patients with Inoperable Cholangiocarcinoma. Cells 2022;11:2309. [DOI: 10.3390/cells11152309] [Reference Citation Analysis]
13 Da Fonseca LG, Hashizume PH, de Oliveira IS, Izquierdo-sanchez L, Saud LRDC, Xerfan MP, Alves VAF, de Mello ES, Herman P, Banales JM, Oliveira CP, Carrilho FJ. Association between Metabolic Disorders and Cholangiocarcinoma: Impact of a Postulated Risk Factor with Rising Incidence. Cancers 2022;14:3483. [DOI: 10.3390/cancers14143483] [Reference Citation Analysis]
14 Qin H, Yuan B, Huang W, Wang Y. Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances. Front Oncol 2022;12:924696. [DOI: 10.3389/fonc.2022.924696] [Reference Citation Analysis]
15 Hwang JA, Lee S, Lee JE, Yoon J, Choi SY, Shin J. LI-RADS Category on MRI Is Associated With Recurrence of Intrahepatic Cholangiocarcinoma After Surgery: A Multicenter Study. J Magn Reson Imaging 2022. [PMID: 35833798 DOI: 10.1002/jmri.28354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yang X, Sun Y, Li D, Xu G, Huang X. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis. Front Immunol 2022;13:940009. [DOI: 10.3389/fimmu.2022.940009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Chiang NJ, Hou YC, Tan KT, Tsai HW, Lin YJ, Yeh YC, Chen LT, Hou YF, Chen MH, Shan YS. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma. Hepatol Int 2022. [PMID: 35780451 DOI: 10.1007/s12072-022-10346-3] [Reference Citation Analysis]
18 Chen Y, Lu Q, Zhu Y, Huang B, Dong Y, Wang W. Prediction of Microvascular Invasion in Combined Hepatocellular-Cholangiocarcinoma Based on Pre-operative Clinical Data and Contrast-Enhanced Ultrasound Characteristics. Ultrasound Med Biol 2022;48:1190-201. [PMID: 35397928 DOI: 10.1016/j.ultrasmedbio.2022.02.014] [Reference Citation Analysis]
19 Chen R, Zheng D, Li Q, Xu S, Ye C, Jiang Q, Yan F, Jia Y, Zhang X, Ruan J. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215853] [Reference Citation Analysis]
20 Shi Z, Zhou L, Zhou Y, Jia X, Yu X, An X, Han Y. Inhibition of ClC-5 suppresses proliferation and induces apoptosis in cholangiocarcinoma cells through the Wnt/β-catenin signaling pathway. BMB Rep 2022;55:299-304. [DOI: 10.5483/bmbrep.2022.55.6.044] [Reference Citation Analysis]
21 Brandi G, Straif K, Mandrioli D, Curti S, Mattioli S, Tavolari S. Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link. Ann Glob Health 2022;88:41. [PMID: 35755315 DOI: 10.5334/aogh.3660] [Reference Citation Analysis]
22 Lin G, Xinhe Z, Haoyu T, Yiling L. Aberrantly methylated-differentially expressed genes and related pathways in cholangiocarcinoma. Medicine (Baltimore) 2022;101:e29379. [PMID: 35758372 DOI: 10.1097/MD.0000000000029379] [Reference Citation Analysis]
23 Kang MJ, Lim J, Han SS, Park HM, Kim SW, Lee WJ, Woo SM, Kim TH, Won YJ, Park SJ. Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study. Sci Rep 2022;12:10206. [PMID: 35715440 DOI: 10.1038/s41598-022-13605-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Nooijen LE, Franken LC, de Boer MT, Buttner S, van Dieren S, Koerkamp BG, Hoogwater FJH, Kazemier G, Klümpen HJ, Kuipers H, Olthof PB, Swijnenburg RJ, Verheij J, Zonderhuis BM, van Gulik TM, Erdmann JI. Value of routine intraoperative frozen sections of proximal bile duct margins in perihilar cholangiocarcinoma, a retrospective multicenter and matched case-control study. Eur J Surg Oncol 2022:S0748-7983(22)00495-4. [PMID: 35729016 DOI: 10.1016/j.ejso.2022.06.011] [Reference Citation Analysis]
25 Liu Y, Yeh MM. Bile duct dysplasia and associated invasive carcinoma: clinicopathological features, diagnosis, and practical challenges. Hum Pathol 2022:S0046-8177(22)00157-5. [PMID: 35714833 DOI: 10.1016/j.humpath.2022.06.012] [Reference Citation Analysis]
26 Weng X, Song X, Shao R, Liu F, Liu Y. Aging and biliary tract cancers: Epidemiology, molecular biology, and clinical practice. Aging and Cancer 2022;3:95-104. [DOI: 10.1002/aac2.12054] [Reference Citation Analysis]
27 Li J, Lu J, Lv S, Sun S, Liu C, Xu F, Sun H, Yang J, Wang X, Zhong X, Lu J. Linoleic acid pathway disturbance contributing to potential cancerization of intrahepatic bile duct stones into intrahepatic cholangiocarcinoma. BMC Gastroenterol 2022;22:269. [PMID: 35637430 DOI: 10.1186/s12876-022-02354-2] [Reference Citation Analysis]
28 Lurje I, Czigany Z, Eischet S, Bednarsch J, Ulmer TF, Isfort P, Strnad P, Trautwein C, Tacke F, Neumann UP, Lurje G. The prognostic impact of preoperative body composition in perihilar and intrahepatic cholangiocarcinoma. Hepatol Commun 2022. [PMID: 35616275 DOI: 10.1002/hep4.2004] [Reference Citation Analysis]
29 Lu C, Miao J, Li M, Zheng Q, Xu F, Pan Y, Wang Y, Yang Z, Xia X, Zhu H, Chen J, Bao S. Characterization of the Estrogen Response Helps to Predict Prognosis and Identify Potential Therapeutic Targets in Cholangiocarcinoma. Front Oncol 2022;12:870840. [DOI: 10.3389/fonc.2022.870840] [Reference Citation Analysis]
30 Deenonpoe R, Sa-Ngiamwibool P, Watcharadetwittaya S, Thanee M, Intuyod K, Kongpan T, Padthaisong S, Nutalai R, Chamgramol Y, Pairojkul C. Fluorescence in situ hybridization detection of chromosome 7 and/or 17 polysomy as a prognostic marker for cholangiocarcinoma. Sci Rep 2022;12:8441. [PMID: 35589822 DOI: 10.1038/s41598-022-11945-8] [Reference Citation Analysis]
31 Martin-Serrano MA, Kepecs B, Torres-Martin M, Bramel ER, Haber PK, Merritt E, Rialdi A, Param NJ, Maeda M, Lindblad KE, Carter JK, Barcena-Varela M, Mazzaferro V, Schwartz M, Affo S, Schwabe RF, Villanueva A, Guccione E, Friedman SL, Lujambio A, Tocheva A, Llovet JM, Thung SN, Tsankov AM, Sia D. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut 2022:gutjnl-2021-326514. [PMID: 35584893 DOI: 10.1136/gutjnl-2021-326514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
32 Seeherunwong A, Chaiear N, Khuntikeo N, Ekpanyaskul C. The Proportion of Occupationally Related Cholangiocarcinoma: A Tertiary Hospital Study in Northeastern Thailand. Cancers 2022;14:2386. [DOI: 10.3390/cancers14102386] [Reference Citation Analysis]
33 Barbato A, Piscopo F, Salati M, Reggiani-bonetti L, Franco B, Carotenuto P. Micro-RNA in Cholangiocarcinoma: Implications for Diagnosis, Prognosis, and Therapy. JMP 2022;3:88-103. [DOI: 10.3390/jmp3020009] [Reference Citation Analysis]
34 Depciuch J, Parlinska-Wojtan M, Rahmi Serin K, Bulut H, Ulukaya E, Tarhan N, Guleken Z. Differential of cholangiocarcinoma disease using Raman spectroscopy combined with multivariate analysis. Spectrochim Acta A Mol Biomol Spectrosc 2022;272:121006. [PMID: 35151168 DOI: 10.1016/j.saa.2022.121006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Carotenuto M, Sacco A, Forgione L, Normanno N. Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2022.00079] [Reference Citation Analysis]
36 Makiuchi T, Sobue T. Descriptive epidemiology of biliary tract cancer incidence and geographic variation in Japan. Eur J Cancer Prev 2022. [PMID: 35485392 DOI: 10.1097/CEJ.0000000000000758] [Reference Citation Analysis]
37 Quan B, Li M, Lu S, Li J, Liu W, Zhang F, Chen R, Ren Z, Yin X. Predicting Disease-Specific Survival for Patients With Primary Cholangiocarcinoma Undergoing Curative Resection by Using a Decision Tree Model. Front Oncol 2022;12:824541. [DOI: 10.3389/fonc.2022.824541] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 de Jong DM, Fritzsche JA, Audhoe AS, Yi SSL, Bruno MJ, Voermans RP, van Driel LMJW. Comparison of Intraductal RFA Plus Stent versus Stent-Only Treatment for Unresectable Perihilar Cholangiocarcinoma—A Systematic Review and Meta-Analysis. Cancers 2022;14:2079. [DOI: 10.3390/cancers14092079] [Reference Citation Analysis]
39 Banas B, Kolodziejczyk P, Czerw A, Banas T, Kotwas A, Richter P. A Retrospective, Single-Centre Study on the Learning Curve for Liver Tumor Open Resection in Patients with Hepatocellular Cancers and Intrahepatic Cholagangiocarcinomas. Int J Environ Res Public Health 2022;19:4872. [PMID: 35457739 DOI: 10.3390/ijerph19084872] [Reference Citation Analysis]
40 Choe JW, Kim HJ, Kim JS. Significance of dysplasia in bile duct resection margin in patients with extrahepatic cholangiocarcinoma: A retrospective analysis. World J Clin Cases 2022; 10(10): 3078-3087 [DOI: 10.12998/wjcc.v10.i10.3078] [Reference Citation Analysis]
41 Silverman IM, Li M, Murugesan K, Krook MA, Javle MM, Kelley RK, Borad MJ, Roychowdhury S, Meng W, Yilmazel B, Milbury C, Shewale S, Feliz L, Burn TC, Albacker LA. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling. J Mol Diagn 2022;24:351-64. [PMID: 35176488 DOI: 10.1016/j.jmoldx.2021.12.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Cowzer D, Harding JJ. Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments. Cancers 2022;14:1800. [DOI: 10.3390/cancers14071800] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
43 Chung T, Park YN. Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma. Front Med 2022;9:857140. [DOI: 10.3389/fmed.2022.857140] [Reference Citation Analysis]
44 Nguyen TK, Nguyen HH, Luong TH, Le VK, Dang KK, Le VD. Right hepatic trisectionectomy combined total caudate lobectomy with non-touch technique for advanced hilar cholangiocarcinoma: A surgical case report (with video). Int J Surg Case Rep 2022;94:106987. [PMID: 35405510 DOI: 10.1016/j.ijscr.2022.106987] [Reference Citation Analysis]
45 Cho IR, Yi SW, Choi JS, Yi JJ. Comparison of Risk Factors for Cholangiocarcinoma and Hepatocellular Carcinoma: A Prospective Cohort Study in Korean Adults. Cancers (Basel) 2022;14:1709. [PMID: 35406481 DOI: 10.3390/cancers14071709] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Li Q, Chen C, Su J, Qiu Y, Wu H, Song T, Mao X, He Y, Cheng Z, Li J, Zhai W, Zhang D, Geng Z, Tang Z. Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection: a multi-institutional study. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09448-w] [Reference Citation Analysis]
47 Vij M, Puri Y, Rammohan A, G G, Rajalingam R, Kaliamoorthy I, Rela M. Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review. World J Gastrointest Oncol 2022; 14(3): 607-627 [DOI: 10.4251/wjgo.v14.i3.607] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Rizzato M, Brignola S, Munari G, Gatti M, Dadduzio V, Borga C, Bergamo F, Pellino A, Angerilli V, Mescoli C, Guido M, Rearden J, Gringeri E, Cillo U, Dei Tos AP, Zagonel V, Loupakis F, Lonardi S, Fassan M. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study. Eur J Cancer 2022;166:165-75. [PMID: 35303508 DOI: 10.1016/j.ejca.2022.02.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Ceci L, Zhou T, Lenci I, Meadows V, Kennedy L, Li P, Ekser B, Milana M, Zhang W, Wu C, Sato K, Chakraborty S, Glaser SS, Francis H, Alpini G, Baiocchi L. Molecular Mechanisms Linking Risk Factors to Cholangiocarcinoma Development. Cancers 2022;14:1442. [DOI: 10.3390/cancers14061442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Jiang H, Li W, Xue Z, Chen W, Zhao L, Song H, Hou J. lncRNA TM4SF1-AS1 predicts dismal outcomes and promotes cholangiocarcinoma progression via modulating miR-744-3p. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101915] [Reference Citation Analysis]
51 Chiow SM, Khoo HW, Low JK, Tan CH, Low HM. Imaging mimickers of cholangiocarcinoma: a pictorial review. Abdom Radiol (NY) 2022;47:981-97. [PMID: 34978593 DOI: 10.1007/s00261-021-03399-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Sumathy B, Dadheech P, Jain M, Saxena A, Hemalatha S, Liu W, Nuagah SJ, Khan W. A Liver Damage Prediction Using Partial Differential Segmentation with Improved Convolutional Neural Network. Journal of Healthcare Engineering 2022;2022:1-14. [DOI: 10.1155/2022/4055491] [Reference Citation Analysis]
53 Oliviero B, Varchetta S, Mele D, Pessino G, Maiello R, Falleni M, Tosi D, Donadon M, Soldani C, Franceschini B, Torzilli G, Piccolo G, Barabino M, Opocher E, Maestri M, Bernuzzi S, Wucherpfennig KW, Mondelli MU, Mantovani S. MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma. OncoImmunology 2022;11:2035919. [DOI: 10.1080/2162402x.2022.2035919] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Pavicevic S, Reichelt S, Uluk D, Lurje I, Engelmann C, Modest DP, Pelzer U, Krenzien F, Raschzok N, Benzing C, Sauer IM, Stinzing S, Tacke F, Schöning W, Schmelzle M, Pratschke J, Lurje G. Prognostic and Predictive Molecular Markers in Cholangiocarcinoma. Cancers 2022;14:1026. [DOI: 10.3390/cancers14041026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Casadio M, Cardinale V, Klümpen H, Morement H, Lacasta A, Koerkamp B, Banales J, Alvaro D, Valle J, Lamarca A. Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). ESMO Open 2022;7:100377. [DOI: 10.1016/j.esmoop.2021.100377] [Reference Citation Analysis]
56 Da Fonseca LG, Forner A. The complexity of cholangiocarcinoma goes beyond clinical practice: Challenges in trials design and interpretation. Liver Int 2022;42:268-70. [PMID: 35092336 DOI: 10.1111/liv.15149] [Reference Citation Analysis]
57 Beri N. Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. Future Oncol 2022. [PMID: 35081733 DOI: 10.2217/fon-2021-1089] [Reference Citation Analysis]
58 Wu H, Ding F, Lin M, Shi Z, Mei Z, Chen S, Jiang C, Qiu H, Zheng Z, Chen Y, Zhao P. Use of the Advanced Lung Cancer Inflammation Index as a Prognostic Indicator for Patients With Cholangiocarcinoma. Front Surg 2022;9:801767. [DOI: 10.3389/fsurg.2022.801767] [Reference Citation Analysis]
59 González MI, Vannan DT, Eksteen B, Flores-sotelo I, Reyes JL. Mast Cells in Immune-Mediated Cholangitis and Cholangiocarcinoma. Cells 2022;11:375. [DOI: 10.3390/cells11030375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Deng J, Liu L, Li L, Sun J, Yan F. Hesperidin delays cell cycle progression into the G0/G1 phase via suspension of MAPK signaling pathway in intrahepatic cholangiocarcinoma. J Biochem Mol Toxicol 2022;:e22981. [PMID: 34984768 DOI: 10.1002/jbt.22981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Zhang G, Liu X, Sun Z, Feng X, Wang H, Hao J, Zhang X. A2M is a potential core gene in intrahepatic cholangiocarcinoma. BMC Cancer 2022;22:5. [PMID: 34979994 DOI: 10.1186/s12885-021-09070-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Panettieri E, Maki H, Kim BJ, Kang HC, Cox V, Vega EA, Mizuno T, Pant S, Javle M, Vauthey JN, Kawaguchi Y. Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma. Surg Oncol 2021;40:101696. [PMID: 34995974 DOI: 10.1016/j.suronc.2021.101696] [Reference Citation Analysis]
63 Sayaf K, Zanotto I, Russo FP, Gabbia D, De Martin S. The Nuclear Receptor PXR in Chronic Liver Disease. Cells 2021;11:61. [PMID: 35011625 DOI: 10.3390/cells11010061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
64 Gutiérrez-Larrañaga M, González-López E, Roa-Bautista A, Rodrigues PM, Díaz-González Á, Banales JM, López-Hoyos M, Santos-Laso A, Crespo J. Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy? Liver Cancer 2021;10:545-60. [PMID: 34950178 DOI: 10.1159/000518104] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
65 Huang X, Niu X, You Z, Long Y, Luo F, Ye H. Comparison of Four Lymph Node Stage Methods for Predicting the Prognosis of Distal Cholangiocarcinoma Patients After Surgery. Front Oncol 2021;11:779761. [PMID: 34926292 DOI: 10.3389/fonc.2021.779761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Gao Y, Ouyang X, Zuo L, Xiao Y, Sun Y, Chang C, Qin X, Yeh S. R-2HG downregulates ERα to inhibit cholangiocarcinoma via the FTO/m6A-methylated ERα/miR16-5p/YAP1 signal pathway. Mol Ther Oncolytics 2021;23:65-81. [PMID: 34632051 DOI: 10.1016/j.omto.2021.06.017] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
67 Phadungsil W, Pumpa S, Sirisabhabhorn K, Geadkaew-Krenc A, Grams R, Mungthin M, Ruang-Areerate T, Adisakwattana P, Labbunruang N, Martviset P. Efficiency of the Stool-PCR Test Targeting NADH Dehydrogenase (Nad) Subunits for Detection of Opisthorchis viverrini Eggs. J Trop Med 2021;2021:3957545. [PMID: 34912461 DOI: 10.1155/2021/3957545] [Reference Citation Analysis]
68 Patrone R, Izzo F, Palaia R, Granata V, Nasti G, Ottaiano A, Pasta G, Belli A. Minimally invasive surgical treatment of intrahepatic cholangiocarcinoma: A systematic review. World J Gastrointest Oncol 2021; 13(12): 2203-2215 [DOI: 10.4251/wjgo.v13.i12.2203] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
69 Zhang T, Zhang S, Jin C, Lin Z, Deng T, Xie X, Deng L, Li X, Ma J, Ding X, Liu Y, Shan Y, Yu Z, Wang Y, Chen G, Li J. A Predictive Model Based on the Gut Microbiota Improves the Diagnostic Effect in Patients With Cholangiocarcinoma. Front Cell Infect Microbiol 2021;11:751795. [PMID: 34888258 DOI: 10.3389/fcimb.2021.751795] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
70 Tang J, Wang R, Tang R, Gu P, Han J, Huang W. CircRTN4IP1 regulates the malignant progression of intrahepatic cholangiocarcinoma by sponging miR-541-5p to induce HIF1A production. Pathol Res Pract 2021;230:153732. [PMID: 34974242 DOI: 10.1016/j.prp.2021.153732] [Reference Citation Analysis]
71 Gruttadauria S, Barbera F, Pagano D, Liotta R, Miraglia R, Barbara M, Bavetta MG, Cammà C, Petridis I, Di Carlo D, Conaldi PG, Di Francesco F. Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling. Cancers (Basel) 2021;13:6049. [PMID: 34885159 DOI: 10.3390/cancers13236049] [Reference Citation Analysis]
72 Fabritius MP, Ben Khaled N, Kunz WG, Ricke J, Seidensticker M. Image-Guided Local Treatment for Unresectable Intrahepatic Cholangiocarcinoma-Role of Interventional Radiology. J Clin Med 2021;10:5574. [PMID: 34884275 DOI: 10.3390/jcm10235574] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Lee TY, Bates SE, Abou-Alfa GK. Equipoise, drug development, and biliary cancer. Cancer 2021. [PMID: 34817855 DOI: 10.1002/cncr.34020] [Reference Citation Analysis]
74 Hao X, Zhang Y, Lu Y, Han G, Rong D, Sun G, Sun G, Tang W, Wu J, Wang X. STK39 enhances the progression of Cholangiocarcinoma via PI3K/AKT pathway. iScience 2021;24:103223. [PMID: 34746696 DOI: 10.1016/j.isci.2021.103223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Gao Y, Liu Y, Sun L, Ouyang X, Zhu C, Qin X. MAD2L1 Functions As a Novel Diagnostic and Predictive Biomarker in Cholangiocarcinoma. Genet Test Mol Biomarkers 2021;25:685-95. [PMID: 34788140 DOI: 10.1089/gtmb.2021.0122] [Reference Citation Analysis]
76 Hewitt DB, Brown ZJ, Pawlik TM. Surgical management of intrahepatic cholangiocarcinoma. Expert Rev Anticancer Ther 2021;:1-12. [PMID: 34730474 DOI: 10.1080/14737140.2022.1999809] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Serifis N, Tsilimigras DI, Cloonan DJ, Pawlik TM. Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma. Hepat Med 2021;13:93-104. [PMID: 34754247 DOI: 10.2147/HMER.S278136] [Reference Citation Analysis]
78 Bekki Y, Von Ahrens D, Takahashi H, Schwartz M, Gunasekaran G. Recurrent Intrahepatic Cholangiocarcinoma - Review. Front Oncol 2021;11:776863. [PMID: 34746017 DOI: 10.3389/fonc.2021.776863] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
79 Rimini M, Puzzoni M, Pedica F, Silvestris N, Fornaro L, Aprile G, Loi E, Brunetti O, Vivaldi C, Simionato F, Zavattari P, Scartozzi M, Burgio V, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol 2021;:1-17. [PMID: 34669536 DOI: 10.1080/17474124.2021.1991313] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
80 Vignone A, Biancaniello F, Casadio M, Pesci L, Cardinale V, Ridola L, Alvaro D. Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review. J Clin Med 2021;10:4901. [PMID: 34768421 DOI: 10.3390/jcm10214901] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
81 Koustas E, Trifylli EM, Sarantis P, Papavassiliou AG, Karamouzis MV. Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy. World J Gastrointest Oncol 2021; 13(10): 1229-1243 [PMID: 34721764 DOI: 10.4251/wjgo.v13.i10.1229] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
82 Ness JR, Molvar C. Radioembolization of Intrahepatic Cholangiocarcinoma: Patient Selection, Outcomes, and Competing Therapies. Semin Intervent Radiol 2021;38:438-44. [PMID: 34629711 DOI: 10.1055/s-0041-1735526] [Reference Citation Analysis]
83 Chatchawal P, Wongwattanakul M, Tippayawat P, Kochan K, Jearanaikoon N, Wood BR, Jearanaikoon P. Detection of Human Cholangiocarcinoma Markers in Serum Using Infrared Spectroscopy. Cancers (Basel) 2021;13:5109. [PMID: 34680259 DOI: 10.3390/cancers13205109] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
84 Macias RIR, Monte MJ, Serrano MA, González-Santiago JM, Martín-Arribas I, Simão AL, Castro RE, González-Gallego J, Mauriz JL, Marin JJG. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging (Albany NY) 2021;13:23416-34. [PMID: 34633987 DOI: 10.18632/aging.203620] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Hunter LA, Soares HP. Quality of Life and Symptom Management in Advanced Biliary Tract Cancers. Cancers (Basel) 2021;13:5074. [PMID: 34680223 DOI: 10.3390/cancers13205074] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
86 Prete MG, Cammarota A, D'alessio A, Zanuso V, Rimassa L. Current options and future directions of systemic therapy for advanced biliary tract cancer. Exploration of Targeted Anti-tumor Therapy 2021;2. [DOI: 10.37349/etat.2021.00054] [Reference Citation Analysis]
87 Panwong S, Wathikthinnakon M, Kaewkod T, Sawasdee N, Tragoolpua Y, Yenchitsomanus PT, Panya A. Cordycepin Sensitizes Cholangiocarcinoma Cells to Be Killed by Natural Killer-92 (NK-92) Cells. Molecules 2021;26:5973. [PMID: 34641520 DOI: 10.3390/molecules26195973] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Shu B, Zhou Y, Liang Q, He C, Li F. HSPB8 promoted intrahepatic cholangiocarcinoma progression by enhancing epithelial-mesenchymal transition and autophagy. Exp Mol Pathol 2021;123:104691. [PMID: 34606781 DOI: 10.1016/j.yexmp.2021.104691] [Reference Citation Analysis]
89 Valle JW, Vogel A, Denlinger CS, He AR, Bai LY, Orlova R, Van Cutsem E, Adeva J, Chen LT, Obermannova R, Ettrich TJ, Chen JS, Wasan H, Girvan AC, Zhang W, Liu J, Tang C, Ebert PJ, Aggarwal A, McNeely SC, Moser BA, Oliveira JM, Carlesi R, Walgren RA, Oh DY. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. Lancet Oncol 2021;22:1468-82. [PMID: 34592180 DOI: 10.1016/S1470-2045(21)00409-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
90 Nooijen LE, Franken LC, Belkouz A, Oulad Abdennabi I, Besselink MG, Busch OR, Swijnenburg RJ, Klümpen HJ, Erdmann JI. Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma: A Retrospective Cohort Study. Am J Clin Oncol 2021;44:526-32. [PMID: 34469345 DOI: 10.1097/COC.0000000000000861] [Reference Citation Analysis]
91 Izquierdo-Sanchez L, Banales JM, Rodrigues PM. A look back at cholangiocarcinoma in Finland. United European Gastroenterol J 2021. [PMID: 34581503 DOI: 10.1002/ueg2.12157] [Reference Citation Analysis]
92 Li X, Yan L, Xue H. Serum epithelial membrane protein 1 serves as a feasible biomarker in extrahepatic cholangiocarcinoma. Int J Biol Markers 2021;36:33-9. [PMID: 34569869 DOI: 10.1177/17246008211035142] [Reference Citation Analysis]
93 Thinkhamrop K, Khuntikeo N, Laohasiriwong W, Chupanit P, Kelly M, Suwannatrai AT. Association of comorbidity between Opisthorchis viverrini infection and diabetes mellitus in the development of cholangiocarcinoma among a high-risk population, northeastern Thailand. PLoS Negl Trop Dis 2021;15:e0009741. [PMID: 34543283 DOI: 10.1371/journal.pntd.0009741] [Reference Citation Analysis]
94 Barner-Rasmussen N, Pukkala E, Hadkhale K, Färkkilä M. Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland. United European Gastroenterol J 2021. [PMID: 34533900 DOI: 10.1002/ueg2.12154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
95 Doi T, Yamamoto N, Naito Y, Kuboki Y, Koyama T, Piao Y, Tsujimoto N, Asou H, Inoue K, Kondo S. Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study. Cancer Med 2021;10:6579-89. [PMID: 34499416 DOI: 10.1002/cam4.4110] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
96 Beetz O, Timrott A, Weigle CA, Schroeter A, Cammann S, Klempnauer J, Vondran FWR, Oldhafer F. Proposal of a New Definition of "Very Early" Intrahepatic Cholangiocarcinoma-A Retrospective Single-Center Analysis. J Clin Med 2021;10:4073. [PMID: 34575181 DOI: 10.3390/jcm10184073] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Zheng YW, Miao XY, Xiong L, Chen B, Kong FH, Zhou JJ, Liu ZT, Wen Y, Zhang ZJ, Zou H. Sulfasalazine Sensitizes Polyhematoporphyrin-Mediated Photodynamic Therapy in Cholangiocarcinoma by Targeting xCT. Front Pharmacol 2021;12:723488. [PMID: 34483935 DOI: 10.3389/fphar.2021.723488] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Murugesan K, Sharaf R, Montesion M, Moore JA, Pao J, Pavlick DC, Frampton GM, Upadhyay VA, Alexander BM, Miller VA, Javle MM, Bekaii Saab TS, Albacker LA, Ross JS, Ali SM. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. JCO Precis Oncol 2021;5:PO. [PMID: 34476330 DOI: 10.1200/PO.20.00397] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Di-Luoffo M, Pirenne S, Saandi T, Loriot A, Gérard C, Dauguet N, Manzano-Núñez F, Alves Souza Carvalhais N, Lamoline F, Cordi S, Konobrocka K, De Greef V, Komuta M, Halder G, Jacquemin P, Lemaigre FP. A Mouse Model of Cholangiocarcinoma Uncovers a Role for Tensin-4 in Tumor Progression. Hepatology 2021;74:1445-60. [PMID: 33768568 DOI: 10.1002/hep.31834] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
100 Hung TH, Hung JT, Wu CE, Huang Y, Lee CW, Yeh CT, Chung YH, Lo FY, Lai LC, Tung JK, Yu J, Yeh CN, Yu AL. Globo H Is a Promising Theranostic Marker for Intrahepatic Cholangiocarcinoma. Hepatol Commun 2021. [PMID: 34558839 DOI: 10.1002/hep4.1800] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
101 Kim GH, Kim PH, Kim JH, Kim PN, Won HJ, Shin YM, Choi SH. Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Eur Radiol 2021. [PMID: 34347159 DOI: 10.1007/s00330-021-08216-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
102 Tseng YT, Hsieh CH, Hung CW, Chen CC, Lee SH, Lee LY, Chen SC. Supportive Care and Unmet Needs in Upper Gastrointestinal Cancer Patients: Screening and Related Factors. Int J Environ Res Public Health 2021;18:8124. [PMID: 34360415 DOI: 10.3390/ijerph18158124] [Reference Citation Analysis]
103 Cavalloni G, Peraldo-Neia C, Massa A, Bergamini C, Trentini A, De Rosa G, Daniele L, Ciccosanti F, Cervellati C, Leone F, Aglietta M. Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients. BMC Cancer 2021;21:865. [PMID: 34320944 DOI: 10.1186/s12885-021-08576-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Loilome W, Dokduang H, Suksawat M, Padthaisong S. Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma. Expert Opin Investig Drugs 2021;:1-22. [PMID: 34292795 DOI: 10.1080/13543784.2021.1955102] [Reference Citation Analysis]
105 Prompipak J, Senawong T, Sripa B, Ketterman AJ, Utaiwat S, Woranam K, Jeeunngoi J, Senawong G. Anticancer effects of the combined Thai noni juice ethanolic extracts and 5-fluorouracil against cholangiocarcinoma cells in vitro and in vivo. Sci Rep 2021;11:14866. [PMID: 34290264 DOI: 10.1038/s41598-021-94049-z] [Reference Citation Analysis]
106 Bednarsch J, Tan X, Czigany Z, Liu D, Lang SA, Sivakumar S, Kather JN, Appinger S, Rosin M, Boroojerdi S, Dahl E, Gaisa NT, den Dulk M, Coolsen M, Ulmer TF, Neumann UP, Heij LR. The Presence of Small Nerve Fibers in the Tumor Microenvironment as Predictive Biomarker of Oncological Outcome Following Partial Hepatectomy for Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:3661. [PMID: 34359564 DOI: 10.3390/cancers13153661] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
107 Fragkou N, Sideras L, Panas P, Emmanouilides C, Sinakos E. Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence? World J Gastroenterol 2021; 27(27): 4252-4275 [PMID: 34366604 DOI: 10.3748/wjg.v27.i27.4252] [Reference Citation Analysis]
108 Liu H, Qiu G, Hu F, Wu H. Fibrinogen/albumin ratio index is an independent predictor of recurrence-free survival in patients with intrahepatic cholangiocarcinoma following surgical resection. World J Surg Oncol 2021;19:218. [PMID: 34284775 DOI: 10.1186/s12957-021-02330-2] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
109 Janthamala S, Jusakul A, Kongpetch S, Kimawaha P, Klanrit P, Loilome W, Namwat N, Techasen A. Arctigenin inhibits cholangiocarcinoma progression by regulating cell migration and cell viability via the N-cadherin and apoptosis pathway. Naunyn Schmiedebergs Arch Pharmacol 2021. [PMID: 34283274 DOI: 10.1007/s00210-021-02123-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Haonon O, Liu Z, Dangtakot R, Intuyod K, Pinlaor P, Puapairoj A, Cha'on U, Sengthong C, Pongking T, Onsurathum S, Yingklang M, Phetcharaburanin J, Li JV, Pinlaor S. Opisthorchis viverrini Infection Induces Metabolic and Fecal Microbial Disturbances in Association with Liver and Kidney Pathologies in Hamsters. J Proteome Res 2021;20:3940-51. [PMID: 34270897 DOI: 10.1021/acs.jproteome.1c00246] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
111 Saldarriaga OA, Dye B, Pham J, Wanninger TG, Millian D, Kueht M, Freiberg B, Utay N, Stevenson HL. Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome. Sci Rep 2021;11:14506. [PMID: 34267267 DOI: 10.1038/s41598-021-93881-7] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
112 Gao K, Chen S, Yang X. HOTTIP Enhances Gemcitabine and Cisplatin Resistance Through Sponging miR-637 in Cholangiocarcinoma. Front Oncol 2021;11:664916. [PMID: 34290981 DOI: 10.3389/fonc.2021.664916] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
113 Baiocchi L, Lenci I, Milana M, Kennedy L, Sato K, Zhang W, Ekser B, Ceci L, Meadows V, Glaser S, Alpini G, Francis H. Cyclic AMP Signaling in Biliary Proliferation: A Possible Target for Cholangiocarcinoma Treatment? Cells 2021;10:1692. [PMID: 34359861 DOI: 10.3390/cells10071692] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
114 Bednarsch J, Czigany Z, Heij LR, Liu D, den Dulk M, Wiltberger G, Bruners P, Ulmer TF, Neumann UP, Lang SA. Compelling Long-Term Results for Liver Resection in Early Cholangiocarcinoma. J Clin Med 2021;10:2959. [PMID: 34209368 DOI: 10.3390/jcm10132959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
115 Rizzo A, Ricci AD, Frega G, Palloni A, DE Lorenzo S, Abbati F, Mollica V, Tavolari S, DI Marco M, Brandi G. How to Choose Between Percutaneous Transhepatic and Endoscopic Biliary Drainage in Malignant Obstructive Jaundice: An Updated Systematic Review and Meta-analysis. In Vivo. 2020;34:1701-1714. [PMID: 32606139 DOI: 10.21873/invivo.11964] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
116 Hatta MNA, Mohamad Hanif EA, Chin SF, Neoh HM. Pathogens and Carcinogenesis: A Review. Biology (Basel) 2021;10:533. [PMID: 34203649 DOI: 10.3390/biology10060533] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
117 Chen W, Song J, Liu S, Tang B, Shen L, Zhu J, Fang S, Wu F, Zheng L, Qiu R, Chen C, Gao Y, Tu J, Zhao Z, Ji J. USP9X promotes apoptosis in cholangiocarcinoma by modulation expression of KIF1Bβ via deubiquitinating EGLN3. J Biomed Sci 2021;28:44. [PMID: 34112167 DOI: 10.1186/s12929-021-00738-2] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
118 Yu H, Wang M, Wang Y, Yang J, Deng L, Bao W, He B, Lin Z, Chen Z, Chen K, Zhang B, Liu F, Yu Z, Ye L, Jin B, Chen G. The prognostic value of sarcopenia combined with preoperative fibrinogen-albumin ratio in patients with intrahepatic cholangiocarcinoma after surgery: A multicenter, prospective study. Cancer Med 2021;10:4768-80. [PMID: 34105304 DOI: 10.1002/cam4.4035] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
119 Chu HH, Kim JH, Shin YM, Won HJ, Kim PN. Percutaneous Radiofrequency Ablation for Recurrent Intrahepatic Cholangiocarcinoma After Curative Resection: Multivariable Analysis of Factors Predicting Survival Outcomes. AJR Am J Roentgenol 2021;217:426-32. [PMID: 34076458 DOI: 10.2214/AJR.20.23461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
120 Yao W, Gong W. Immunotherapy in cholangiocarcinoma: From concept to clinical trials. Surgery in Practice and Science 2021;5:100028. [DOI: 10.1016/j.sipas.2021.100028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
121 Yu J, Zhang X, Huang Q, Tan S, Xiong X, Gou H. Rare DNA Mismatch Repair-Related Protein Loss in Patients with Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma and Their Response to Immunotherapy. Cancer Manag Res 2021;13:4283-90. [PMID: 34113169 DOI: 10.2147/CMAR.S304281] [Reference Citation Analysis]
122 Panayotova G, Guerra J, Guarrera JV, Lunsford KE. The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2428. [PMID: 34070772 DOI: 10.3390/jcm10112428] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
123 Casadio M, Biancaniello F, Overi D, Venere R, Carpino G, Gaudio E, Alvaro D, Cardinale V. Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine. Int J Mol Sci 2021;22:5613. [PMID: 34070643 DOI: 10.3390/ijms22115613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
124 Dangtakot R, Intuyod K, Chamgramol Y, Pairojkul C, Pinlaor S, Jantawong C, Pongking T, Haonon O, Ma N, Pinlaor P. CagA+ Helicobacter pylori infection and N-nitrosodimethylamine administration induce cholangiocarcinoma development in hamsters. Helicobacter 2021;26:e12817. [PMID: 34031944 DOI: 10.1111/hel.12817] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Rompianesi G, Di Martino M, Gordon-Weeks A, Montalti R, Troisi R. Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. World J Gastrointest Oncol 2021;13:332-50. [PMID: 34040697 DOI: 10.4251/wjgo.v13.i5.332] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
126 Izumiya M, Kato S, Hippo Y. Recent Advances in Implantation-Based Genetic Modeling of Biliary Carcinogenesis in Mice. Cancers (Basel) 2021;13:2292. [PMID: 34064809 DOI: 10.3390/cancers13102292] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
127 Rizzo A, Ricci AD, Tavolari S, Brandi G. Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. Cancer Genomics Proteomics. 2020;17:441-452. [PMID: 32859625 DOI: 10.21873/cgp.20203] [Cited by in Crossref: 38] [Cited by in F6Publishing: 60] [Article Influence: 38.0] [Reference Citation Analysis]
128 Chen Y, Wang W. Differentiation between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced ultrasound: A systematic review and meta-analysis. Clin Hemorheol Microcirc 2021. [PMID: 33935070 DOI: 10.3233/CH-211145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Bekaii-Saab TS, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol 2021;32:1111-26. [PMID: 33932504 DOI: 10.1016/j.annonc.2021.04.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
130 Cigliano A, Chen X, Calvisi DF. Current challenges to underpinning the genetic basis for cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2021;15:511-26. [PMID: 33888034 DOI: 10.1080/17474124.2021.1915128] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
131 Lee PC, Hendifar A, Osipov A, Cho M, Li D, Gong J. Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations. Cancers (Basel) 2021;13:1706. [PMID: 33916849 DOI: 10.3390/cancers13071706] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
132 Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treatment Reviews 2021;95:102170. [DOI: 10.1016/j.ctrv.2021.102170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
133 Boilève A, Hilmi M, Smolenschi C, Ducreux M, Hollebecque A, Malka D. Immunotherapy in Advanced Biliary Tract Cancers. Cancers (Basel) 2021;13:1569. [PMID: 33805461 DOI: 10.3390/cancers13071569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
134 Takihata Y, Einama T, Kobayashi K, Suzuki T, Yonamine N, Fujinuma I, Tsunenari T, Yamagishi Y, Iwasaki T, Miyata Y, Shinto E, Ogata S, Tsujimoto H, Ueno H, Kishi Y. Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma. Oncol Lett 2021;21:414. [PMID: 33841575 DOI: 10.3892/ol.2021.12675] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
135 Fung BM, Tabibian JH. Primary sclerosing cholangitis-associated cholangiocarcinoma: special considerations and best practices. Expert Rev Gastroenterol Hepatol 2021;15:487-96. [PMID: 33682586 DOI: 10.1080/17474124.2021.1900732] [Reference Citation Analysis]
136 Saab M, Mestivier D, Sohrabi M, Rodriguez C, Khonsari MR, Faraji A, Sobhani I. Characterization of biliary microbiota dysbiosis in extrahepatic cholangiocarcinoma. PLoS One 2021;16:e0247798. [PMID: 33690612 DOI: 10.1371/journal.pone.0247798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
137 Pericleous M, Khan SA. Epidemiology of HPB malignancy in the elderly. European Journal of Surgical Oncology 2021;47:503-13. [DOI: 10.1016/j.ejso.2020.03.222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
138 Kulma I, Panrit L, Plengsuriyakarn T, Chaijaroenkul W, Warathumpitak S, Na-Bangchang K. A randomized placebo-controlled phase I clinical trial to evaluate the immunomodulatory activities of Atractylodes lancea (Thunb) DC. in healthy Thai subjects. BMC Complement Med Ther 2021;21:61. [PMID: 33579265 DOI: 10.1186/s12906-020-03199-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Xu S, Guo Y, Zeng Y, Song Z, Zhu X, Fan N, Zhang Z, Ren G, Zang Y, Rao W. Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma. BMC Cancer 2021;21:152. [PMID: 33579226 DOI: 10.1186/s12885-021-07792-x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
140 Katanoda K, Hori M, Saito E, Shibata A, Ito Y, Minami T, Ikeda S, Suzuki T, Matsuda T. Updated Trends in Cancer in Japan: Incidence in 1985-2015 and Mortality in 1958-2018-A Sign of Decrease in Cancer Incidence. J Epidemiol 2021;31:426-50. [PMID: 33551387 DOI: 10.2188/jea.JE20200416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
141 Na-Bangchang K, Kulma I, Plengsuriyakarn T, Tharavanij T, Kotawng K, Chemung A, Muhamad N, Karbwang J. Phase I clinical trial to evaluate the safety and pharmacokinetics of capsule formulation of the standardized extract of Atractylodes lancea. J Tradit Complement Med 2021;11:343-55. [PMID: 34195029 DOI: 10.1016/j.jtcme.2021.02.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
142 Li O, Jiang B, Yi WM, Zhang Y, Yang PZ, Guo C, Sun ZP, Peng C. LncRNA NEAT1 promotes cell proliferation, migration, and invasion via the miR-186-5p/PTP4A1 axis in cholangiocarcinoma. Kaohsiung J Med Sci 2021;37:379-91. [PMID: 33502823 DOI: 10.1002/kjm2.12354] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
143 Digifico E, Balinzo S, Belgiovine C. The Dark Side of the Force: When the Immune System Is the Fuel of Tumor Onset. Int J Mol Sci 2021;22:1224. [PMID: 33513730 DOI: 10.3390/ijms22031224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Raggi C, Taddei ML, Sacco E, Navari N, Correnti M, Piombanti B, Pastore M, Campani C, Pranzini E, Iorio J, Lori G, Lottini T, Peano C, Cibella J, Lewinska M, Andersen JB, di Tommaso L, Viganò L, Di Maira G, Madiai S, Ramazzotti M, Orlandi I, Arcangeli A, Chiarugi P, Marra F. Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. J Hepatol 2021;74:1373-85. [PMID: 33484774 DOI: 10.1016/j.jhep.2020.12.031] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
145 Muñoz-Martínez S, Forner A. The tireless search to improve the prognostic assessment of intrahepatic cholangiocarcinoma: An urgent need. Liver Int 2021;41:252-4. [PMID: 33464725 DOI: 10.1111/liv.14768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
146 Moeini A, Haber PK, Sia D. Cell of origin in biliary tract cancers and clinical implications. JHEP Rep 2021;3:100226. [PMID: 33665585 DOI: 10.1016/j.jhepr.2021.100226] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
147 Burton A, Tataru D, Driver RJ, Bird TG, Huws D, Wallace D, Cross TJS, Rowe IA, Alexander G, Marshall A; HCC-UK/BASL/NCRAS Partnership Steering Group. Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation. JHEP Rep 2021;3:100232. [PMID: 33748727 DOI: 10.1016/j.jhepr.2021.100232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
148 Dangtakot R, Intuyod K, Ahooja A, Wongwiwatchai J, Hanpanich P, Lulitanond A, Chamgramol Y, Pinlaor S, Pinlaor P. Profiling of Bile Microbiome Identifies District Microbial Population between Choledocholithiasis and Cholangiocarcinoma Patients. Asian Pac J Cancer Prev 2021;22:233-40. [PMID: 33507704 DOI: 10.31557/APJCP.2021.22.1.233] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
149 Ketpueak T, Thiennimitr P, Apaijai N, Chattipakorn SC, Chattipakorn N. Association of Chronic Opisthorchis Infestation and Microbiota Alteration on Tumorigenesis in Cholangiocarcinoma. Clin Transl Gastroenterol 2020;12:e00292. [PMID: 33464733 DOI: 10.14309/ctg.0000000000000292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
150 Ofoeyeno N, Ekpenyong E, Braconi C. Pathogenetic Role and Clinical Implications of Regulatory RNAs in Biliary Tract Cancer. Cancers (Basel) 2020;13:E12. [PMID: 33375055 DOI: 10.3390/cancers13010012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
151 Tan X, Sivakumar S, Bednarsch J, Wiltberger G, Kather JN, Niehues J, de Vos-Geelen J, Valkenburg-van Iersel L, Kintsler S, Roeth A, Hao G, Lang S, Coolsen ME, den Dulk M, Aberle MR, Koolen J, Gaisa NT, Olde Damink SWM, Neumann UP, Heij LR. Nerve fibers in the tumor microenvironment in neurotropic cancer-pancreatic cancer and cholangiocarcinoma. Oncogene 2021;40:899-908. [PMID: 33288884 DOI: 10.1038/s41388-020-01578-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
152 Xu JL, Guo Y. FCGR1A Serves as a Novel Biomarker and Correlates With Immune Infiltration in Four Cancer Types. Front Mol Biosci 2020;7:581615. [PMID: 33344503 DOI: 10.3389/fmolb.2020.581615] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
153 Rizzo A, Frega G, Ricci AD, Palloni A, Abbati F, DE Lorenzo S, Deserti M, Tavolari S, Brandi G. Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis. In Vivo 2020;34:479-88. [PMID: 32111744 DOI: 10.21873/invivo.11798] [Cited by in Crossref: 12] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
154 Li J, Yang Z, Huang S, Li D. BIRC7 and STC2 Expression Are Associated With Tumorigenesis and Poor Outcome in Extrahepatic Cholangiocarcinoma. Technol Cancer Res Treat 2020;19:1533033820971676. [PMID: 33234031 DOI: 10.1177/1533033820971676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
155 Machairas N, Kostakis ID, Schizas D, Kykalos S, Nikiteas N, Sotiropoulos GC. Meta-analysis of laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma. Updates Surg 2021;73:59-68. [PMID: 33219937 DOI: 10.1007/s13304-020-00930-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
156 Brandi G, Rizzo A, Deserti M, Relli V, Indio V, Bin S, Pariali M, Palloni A, De Lorenzo S, Tovoli F, Tavolari S. Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster. BMC Med Genet 2020;21:225. [PMID: 33208122 DOI: 10.1186/s12881-020-01165-0] [Reference Citation Analysis]
157 Huang YH, Zhang CZ, Huang QS, Yeong J, Wang F, Yang X, He YF, Zhang XL, Zhang H, Chen SL, Zheng YL, Deng R, Lin CS, Yang MM, Li Y, Jiang C, Kin-Wah Lee T, Ma S, Zeng MS, Yun JP. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma. J Hepatol 2021;74:838-49. [PMID: 33212090 DOI: 10.1016/j.jhep.2020.10.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
158 Personeni N, Lleo A, Pressiani T, Colapietro F, Openshaw MR, Stavraka C, Pouptsis A, Pinato DJ, Rimassa L. Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers (Basel) 2020;12:E3370. [PMID: 33202975 DOI: 10.3390/cancers12113370] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
159 Chatchawal P, Wongwattanakul M, Tippayawat P, Jearanaikoon N, Jumniansong A, Boonmars T, Jearanaikoon P, Wood BR. Monitoring the Progression of Liver Fluke-Induced Cholangiocarcinoma in a Hamster Model Using Synchrotron FTIR Microspectroscopy and Focal Plane Array Infrared Imaging. Anal Chem 2020;92:15361-9. [PMID: 33170647 DOI: 10.1021/acs.analchem.0c02656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
160 Gopinathan P, Chiang N, Wang C, Sinha A, Tsai Y, Tu H, Hung S, Hsu P, Shan Y, Lee G. Aptamer probed isolation of circulating tumor cells in cholangiocarcinoma patients. Sensors and Actuators B: Chemical 2020;322:128569. [DOI: 10.1016/j.snb.2020.128569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
161 Omar AI, Plengsuriyakarn T, Chittasupho C, Na-Bangchang K. Enhanced oral bioavailability and biodistribution of atractylodin encapsulated in PLGA nanoparticle in cholangiocarcinoma. Clin Exp Pharmacol Physiol 2021;48:318-28. [PMID: 33125766 DOI: 10.1111/1440-1681.13433] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
162 Lacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K, Abou-Alfa G. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines. Oncologist 2021;26:e316-26. [PMID: 33021006 DOI: 10.1002/onco.13552] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
163 Fung BM, Tabibian JH. Cholangiocarcinoma in patients with primary sclerosing cholangitis.Curr Opin Gastroenterol. 2020;36:77-84. [PMID: 31850928 DOI: 10.1097/MOG.0000000000000616] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
164 Brandi G, Deserti M, Palloni A, Turchetti D, Zuntini R, Pedica F, Frega G, De Lorenzo S, Abbati F, Rizzo A, Di Marco M, Massari F, Tavolari S. Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos. Cancer Genet 2020;248-249:57-62. [PMID: 33093002 DOI: 10.1016/j.cancergen.2020.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
165 Wijetunga I, McVeigh LE, Charalambous A, Antanaviciute A, Carr IM, Nair A, Prasad KR, Ingram N, Coletta PL. Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review. Cancers (Basel) 2020;12:E2817. [PMID: 33007872 DOI: 10.3390/cancers12102817] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
166 Gilliaux Q, Faugeras L, Martinet JP, De Ronde T, Badaoui A, Bertrand C, Dili A, Delos M, Jamart J, Baily A, D'Hondt L. Incidence and Prognosis of Biliary Tract and Gallbladder Cancers in a Belgian Academic Hospital. J Gastrointest Cancer 2021;52:1003-9. [PMID: 32984916 DOI: 10.1007/s12029-020-00526-5] [Reference Citation Analysis]
167 Ranieri G, Laface C. Loco-Regional and Systemic Chemotherapies for Hepato-Pancreatic Tumors: Integrated Treatments. Cancers (Basel) 2020;12:E2737. [PMID: 32987630 DOI: 10.3390/cancers12102737] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
168 Rauff B, Malik A, Bhatti YA, Chudhary SA, Qadri I, Rafiq S. Notch signalling pathway in development of cholangiocarcinoma. World J Gastrointest Oncol 2020; 12(9): 957-974 [PMID: 33005291 DOI: 10.4251/wjgo.v12.i9.957] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
169 Arteta AA, Milanes-Yearsley M, Cardona-Castro N. Cholangiocyte derived carcinomas and local microbiota. J Hepatobiliary Pancreat Sci 2020. [PMID: 32902144 DOI: 10.1002/jhbp.826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Polidoro MA, Mikulak J, Cazzetta V, Lleo A, Mavilio D, Torzilli G, Donadon M. Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. World J Gastroenterol 2020; 26(33): 4900-4918 [PMID: 32952338 DOI: 10.3748/wjg.v26.i33.4900] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
171 Cholangiocarcinoma Working Group. Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part I: Classification, diagnosis and staging. Dig Liver Dis 2020;52:1282-93. [PMID: 32893173 DOI: 10.1016/j.dld.2020.06.045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
172 Crispo F, Pietrafesa M, Condelli V, Maddalena F, Bruno G, Piscazzi A, Sgambato A, Esposito F, Landriscina M. IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives. Molecules 2020;25:E3754. [PMID: 32824685 DOI: 10.3390/molecules25163754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
173 Massa A, Varamo C, Vita F, Tavolari S, Peraldo-Neia C, Brandi G, Rizzo A, Cavalloni G, Aglietta M. Evolution of the Experimental Models of Cholangiocarcinoma. Cancers (Basel) 2020;12:E2308. [PMID: 32824407 DOI: 10.3390/cancers12082308] [Cited by in Crossref: 40] [Cited by in F6Publishing: 48] [Article Influence: 20.0] [Reference Citation Analysis]
174 Zhou T, Liu L, Dai HS, Zhang CC, He Y, Zhang LD, Li DJ, Bie P, Ding J, Chen ZY; other members of the Hilar Cholangiocarcinoma Study Group. Impact of body mass index on postoperative outcomes in patients undergoing radical resection for hilar cholangiocarcinoma. J Surg Oncol 2020;122:1418-25. [PMID: 32794267 DOI: 10.1002/jso.26172] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Malenica I, Donadon M, Lleo A. Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine. Cancers (Basel) 2020;12:E2190. [PMID: 32781527 DOI: 10.3390/cancers12082190] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
176 Xie C, McGrath NA, Monge Bonilla C, Fu J. Systemic treatment options for advanced biliary tract carcinoma. J Gastroenterol 2020;55:944-57. [PMID: 32748173 DOI: 10.1007/s00535-020-01712-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
177 Marin JJG, Prete MG, Lamarca A, Tavolari S, Landa-Magdalena A, Brandi G, Segatto O, Vogel A, Macias RIR, Rodrigues PM, Casta A, Mertens J, Rodrigues CMP, Fernandez-Barrena MG, Da Silva Ruivo A, Marzioni M, Mentrasti G, Acedo P, Munoz-Garrido P, Cardinale V, Banales JM, Valle JW, Bridgewater J, Braconi C; working group 6 of the COST-action 18122 (Euro-Cholangio-NET) as part of the European Network for the study of Cholangiocarcinoma (ENSCCA). Current and novel therapeutic opportunities for systemic therapy in biliary cancer. Br J Cancer 2020;123:1047-59. [PMID: 32694694 DOI: 10.1038/s41416-020-0987-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
178 Xiong F, Gong J, Wang Q. Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report. Onco Targets Ther 2020;13:6385-91. [PMID: 32753881 DOI: 10.2147/OTT.S250454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
179 Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557-588. [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z] [Cited by in Crossref: 456] [Cited by in F6Publishing: 438] [Article Influence: 228.0] [Reference Citation Analysis]
180 Kingham TP, Aveson VG, Wei AC, Castellanos JA, Allen PJ, Nussbaum DP, Hu Y, D'Angelica MI. Surgical management of biliary malignancy. Curr Probl Surg 2021;58:100854. [PMID: 33531120 DOI: 10.1016/j.cpsurg.2020.100854] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
181 Manieri E, Folgueira C, Rodríguez ME, Leiva-Vega L, Esteban-Lafuente L, Chen C, Cubero FJ, Barrett T, Cavanagh-Kyros J, Seruggia D, Rosell A, Sanchez-Cabo F, Gómez MJ, Monte MJ, G Marin JJ, Davis RJ, Mora A, Sabio G. JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma. Proc Natl Acad Sci U S A 2020;117:16492-9. [PMID: 32601222 DOI: 10.1073/pnas.2002672117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
182 Ariake K, Unno M, Yoshida H, Kubo S, Horiguchi A, Yamaue H, Yamamoto M. Risk factors and characteristics of young patients with the biliary tract carcinoma: results of a project study for biliary surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2020;27:571-80. [PMID: 32510820 DOI: 10.1002/jhbp.776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
183 Alenezi AO, Krishna S, Mendiratta-Lala M, Kielar AZ. Imaging and Management of Liver Cancer. Semin Ultrasound CT MR 2020;41:122-38. [PMID: 32446427 DOI: 10.1053/j.sult.2019.12.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
184 Brandi G, Rizzo A, Dall’olio FG, Felicani C, Ercolani G, Cescon M, Frega G, Tavolari S, Palloni A, De Lorenzo S, Abbati F, Mollica V, Ricci AD, Serra C. Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. International Journal of Hyperthermia 2020;37:479-85. [DOI: 10.1080/02656736.2020.1763484] [Cited by in Crossref: 19] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
185 Yin X, Chai Z, Sun X, Chen J, Wu X, Yang L, Zhou X, Liu F. Overexpression of microRNA-96 is associated with poor prognosis and promotes proliferation, migration and invasion in cholangiocarcinoma cells via MTSS1. Exp Ther Med 2020;19:2757-65. [PMID: 32256758 DOI: 10.3892/etm.2020.8502] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
186 Arunsan P, Chaidee A, Cochran CJ, Mann VH, Tanno T, Kumkhaek C, Smout MJ, Karinshak SE, Rodpai R, Sotillo J, Loukas A, Laha T, Brindley PJ, Ittiprasert W. Liver fluke granulin promotes extracellular vesicle-mediated crosstalk and cellular microenvironment conducive to cholangiocarcinoma. Neoplasia 2020;22:203-16. [PMID: 32244128 DOI: 10.1016/j.neo.2020.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
187 Dasgupta P, Henshaw C, Youlden DR, Clark PJ, Aitken JF, Baade PD. Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:171. [PMID: 32185125 DOI: 10.3389/fonc.2020.00171] [Cited by in Crossref: 29] [Cited by in F6Publishing: 55] [Article Influence: 14.5] [Reference Citation Analysis]
188 Brandi G, Tavolari S. Asbestos and Intrahepatic Cholangiocarcinoma. Cells 2020;9:E421. [PMID: 32059499 DOI: 10.3390/cells9020421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
189 Asahi Y, Hatanaka KC, Hatanaka Y, Kamiyama T, Orimo T, Shimada S, Nagatsu A, Sakamoto Y, Kamachi H, Kobayashi N, Fukai M, Taketomi A. Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma. Surg Today. 2020;50:931-940. [PMID: 32040618 DOI: 10.1007/s00595-020-01967-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
190 Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. Journal of Hepatology 2020;72:353-63. [DOI: 10.1016/j.jhep.2019.10.009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 103] [Article Influence: 28.0] [Reference Citation Analysis]
191 Machairas N, Lang H, Jayant K, Raptis DA, Sotiropoulos GC. Intrahepatic cholangiocarcinoma: Limitations for resectability, current surgical concepts and future perspectives. Eur J Surg Oncol 2020;46:740-6. [PMID: 32007379 DOI: 10.1016/j.ejso.2020.01.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
192 Win Maung HM, Chan-On W, Kunkeaw N, Khaenam P. Common transcriptional programs and the role of chemokine (C-C motif) ligand 20 (CCL20) in cell migration of cholangiocarcinoma. EXCLI J 2020;19:154-66. [PMID: 32194362 DOI: 10.17179/excli2019-1893] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
193 Choe JW, Kim HJ, Kim JS. Survival improvement and prognostic factors in recent management of extrahepatic cholangiocarcinoma: A single-center study. Hepatobiliary Pancreat Dis Int 2020;19:153-6. [PMID: 31974040 DOI: 10.1016/j.hbpd.2019.12.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
194 Chen X, Sun S, Yan X, Fu X, Fan Y, Chen D, Qiu Y, Mao L. Predictive Factors and Microbial Spectrum for Infectious Complications after Hepatectomy with Cholangiojejunostomy in Perihilar Cholangiocarcinoma. Surg Infect (Larchmt) 2020;21:275-83. [PMID: 31710266 DOI: 10.1089/sur.2019.199] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
195 Chen B, Fu SW, Lu L, Zhao H. A Preliminary Study of Biliary Microbiota in Patients with Bile Duct Stones or Distal Cholangiocarcinoma. Biomed Res Int 2019;2019:1092563. [PMID: 31662965 DOI: 10.1155/2019/1092563] [Cited by in Crossref: 9] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
196 Yang H, Wang J, Li Z, Yang Y, Yang L, Zhang Y, Shi Y, Cao Y, Zhou J, Wang Z, Chen Q. Risk Factors and Outcomes of Early Relapse After Curative Resection of Intrahepatic Cholangiocarcinoma. Front Oncol 2019;9:854. [PMID: 31555597 DOI: 10.3389/fonc.2019.00854] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
197 Chahinian R, El-Amine A, Matar S, Annan M, Shamseddine A, Haidar M. 68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma. Asia Ocean J Nucl Med Biol 2020;8:136-40. [PMID: 32715002 DOI: 10.22038/AOJNMB.2020.46939.1314] [Reference Citation Analysis]